Skip to main content

Table 1 Patients demographic and clinical characteristics

From: High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial

Clinical variables

Low-dose group (n = 70)

High-dose group (n = 70)

p-value

Female gender, n (%)

52 (74.3)

49 (70.0)

0.575

Age (years), mean ± SD

78.5 ± 9.3

80.1 ± 10.0

0.311

Body mass index (kg/m2), mean ± SD

22.7 ± 3.6

22.5 ± 4.2

0.731

Charlson comorbidity index (CCI)

 - 0–1

46 (65.7)

47 (67.1)

0.840

 - 2–3

23 (32.9)

21 (30.0)

 

 - >  3

1 (1.4)

2 (2.9)

 

Type of hip fracture, n (%)

 - Intertrochanteric fracture

34 (48.6)

38 (54.3)

0.112

 - Femoral neck fracture

36 (51.4)

32 (45.7)

 

Treatment, n (%)

 - Conservative

1 (1.4)

2 (2.9)

0.691

 - Multiple screw fixation

3 (4.3)

2 (2.9)

 

 - Dynamic hip screw fixation

8 (11.4)

4 (5.7)

 

 - Intramedullary nailing

30 (42.9)

33 (47.1)

 

 - Arthroplasty

28 (40.0)

29 (41.4)

 

Previous functional status, n (%)

 - Outdoor

48 (68.6)

40 (57.1)

0.235

 - Indoor

22 (31.4)

30 (42.9)

 

Pre-operative ambulatory status, n (%)

 - Independent without gait aid

43 (61.4)

39 (55.7)

0.372

 - Single cane

16 (22.9)

14 (20.0)

 

 - Tripod cane

3 (4.3)

6 (8.6)

 

 - Quad cane

0 (0)

0 (0)

 

 - Pick up walker

7 (10.0)

8 (11.4)

 

 - Wheel chair

0 (0.0)

2 (2.9)

 

 - Bed bound

1 (1.4)

1 (1.4)

Â